CXCL5 Antibody

中文名稱：

CXCL5兔多克隆抗體
貨號：

CSB-PA06155A0Rb
規(guī)格：

￥440
圖片：
Western blot
All lanes: CXCL5 antibody at 2µg/ml + 293T whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/15000 dilution
Predicted band size: 12 kDa
Observed band size: 90 kDa
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) CXCL5 Polyclonal antibody
Uniprot No.：

P42830
基因名：

CXCL5
別名：

AMCFII antibody; C-X-C motif chemokine 5 antibody; C-X-C motif chemokine ligand 5 antibody; Chemokine (C X C motif) ligand 5 antibody; chemokine (C-X-C motif) ligand 5 antibody; Cxcl5 antibody; CXCL5_HUMAN antibody; ENA 78 antibody; ENA-78 (8-78) antibody; ENA-78(1-78) antibody; ENA-78(9-78) antibody; ENA78 antibody; Epithelial derived neutrophil activating protein 78 antibody; Epithelial-derived neutrophil-activating protein 78 antibody; Lipopolysaccharide-induced CXC chemokine antibody; Neutrophil activating peptide ENA 78 antibody; Neutrophil activating protein 78 antibody; Neutrophil-activating peptide ENA-78 antibody; neutrophil-activating protein 78 antibody; SCYB5 antibody; Small inducible cytokine B5 antibody; small inducible cytokine subfamily B (Cys-X-Cys); member 5 (epithelial-derived neutrophil-activating peptide 78) antibody; small inducible cytokine subfamily B; member 5 antibody; Small-inducible cytokine B5 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human C-X-C motif chemokine 5 protein (37-110AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，CXCL5 Antibody (CSB-PA06155A0Rb)，的標(biāo)記方式是Non-conjugated。對于CXCL5 Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA06155B0Rb	CXCL5 Antibody, HRP conjugated	ELISA
FITC	CSB-PA06155C0Rb	CXCL5 Antibody, FITC conjugated
Biotin	CSB-PA06155D0Rb	CXCL5 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB

推薦稀釋比：

Application	Recommended Dilution
WB	1:1000-1:5000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Involved in neutrophil activation. In vitro, ENA-78(8-78) and ENA-78(9-78) show a threefold higher chemotactic activity for neutrophil granulocytes.
基因功能參考文獻(xiàn)：
1. Serum CXCL5 levels from pemphigus vulgaris patients are significantly higher than those in bullous pemphigoid patients and healthy controls. PMID: 27501402
2. These data demonstrated that CXCL5 expression was upregulated in prostate cancer tissues and that exogenous CXCL5 protein exposure or CXCL5 overexpression promoted malignant phenotypes of prostate cancer cells in vitro and in vivo. PMID: 29749439
3. activated CXCL5-CXCR2 axis contributes to the metastatic phenotype of PTC cells by modulating Akt/GSK-3beta/beta-catenin pathway PMID: 29471001
4. study elucidates the important role of CXCL5 in the progression and prognosis of NSCLC. These findings suggested that CXCL5 might be a potential biomarker and novel therapeutic target for lung cancer PMID: 29526026
5. PERK-p-eIF2alpha pathway could suppress metastasis in triple-negative breast cancer by inhibiting expression of PDL1 and CXCL5 in tumor cells. PMID: 29053414
6. Mechanistically, AR modulated cytokine CXCL5 expression by altering AKT --> NF-kappaB signaling, and interruption of AKT --> NF-kappaB --> CXCL5 signaling using either specific inhibitors or siRNA suppressed AR-enhanced EC recruitment and AR-EC-promoted RCC progression. PMID: 27848972
7. Curcumin suppressed CXCL5 expression by direct inhibition of IKKbeta phosphorylation, and inhibition of p38 MAPK via induction of negative regulator MKP-1. PMID: 27538525
8. The CXCL5 and the overexpression of miR-141 reduced levels of MMP-2 and MMP-9 in tumor necrosis factor-alpha-treated HT29 cells by means of repressing the inhibitory AKT. PMID: 28854064
9. CXCL5 may promote mitomycin resistance by activating EMT and NF-kappaB pathway. Thus, this study identifies CXCL5 as a novel chemoresistance-related marker in non-muscle invasive bladder cancer PMID: 29545183
10. findings for the first time provided evidence that ENA78 may play a key role of mediator in pathogenesis of Major Depressive Disorder(MDD) and in the mechanism of vinlafaxine effects on MDD. PMID: 28441588
11. our findings support CXCL5 as a promoter of colorectal cancer metastasis and a predictor of poor clinical outcomes in colorectal cancer patients. PMID: 28356111
12. CXCL5 levels were decreased in LSCC patient serum. PMID: 27876461
13. a finely tuned balance between the GAG-bound dimer and free soluble monomer regulates CXCL5-mediated receptor signaling and function. PMID: 27471273
14. CXCL5 plays a promoting role in glioma in autocrine- and paracrine-dependent manners. PMID: 27748886
15. The expression of CXCL5 is up-regulated in osteosarcoma cells. PMID: 28277189
16. CXCL5 expression in urine is related to bladder cancer TNM stage, lymph node metastasis, tumor size, and tumor grade. PMID: 26503215
17. ENA 78 plasma levels were correlated with Expanded Disability Status Scale scores in neuromyelitis optica (NMO) patients; elevated secretion of ENA 78 may be a critical step in neutrophil recruitment during the remission of NMO. PMID: 27401736
18. CXCL5 expression is enriched in human atherosclerotic coronary artery. The CXCL5 variant might be a genetic risk factor for the susceptibility of CAD and the CXCL5 promoter -156 G/C C allele might be an independent predictor for CAD. PMID: 26287498
19. Study shows that CXCL5 expression is elevated in positive correlation to bladder cancer grade and promotes cell migration and invasion via binding to its receptor CXCR2. PMID: 26058729
20. Analysis of monocultured dermal fibroblasts and keratinocytes revealed that only fibroblasts but not keratinocytes displayed up regulated CXCL5 levels after UV stimulation. PMID: 25690483
21. There was an inverse correlation between DACH1 mRNA levels and CXCL5 in both lung cancer cell lines and human NSCLC tissues. PMID: 25788272
22. High CXCL5 expression is associated with pediatric ulcerative colitis. PMID: 25738378
23. the increased level of CXCL5 in tissue compartments, including the central nervous system of HIV-1-infected individuals might alter the inflammatory response through the infiltration of neutrophils into tissue compartment PMID: 25536401
24. Serum levels of ENA-78 were elevated in autistic children and they were significantly associated with the increased levels of serum antineuronal auto-antibodies PMID: 25871636
25. This study aims to evaluate serum levels of ENA78/CXCL5 and SDF-1/CXCL12 along the gastric cancer carcinogenesis, and analyze their clinical significance, and diagnostic potentials through human serum samples. PMID: 25689618
26. our data showed that the CXCR2/CXCL5 axis contributes to EMT of HCC cells through activating PI3K/Akt/GSK-3beta/Snail signaling, and it may serve as a potential therapeutic target. PMID: 25462858
27. Solution structure of CXCL5--a novel chemokine and adipokine implicated in inflammation and obesity PMID: 24695525
28. the expression levels of CXCL5 proteins were decreased in dermal blood vessels of early stage diffuse cutaneous systemic sclerosis PMID: 24292093
29. data indicates that LCCs per se may act as the producer and receptor of CXCL5 responsible for liver cancer migration and invasion PMID: 25011526
30. Citrullinated ENA-78/CXCL5 is highly correlated with rheumatoid arthritis disease activity and, unlike noncitrullinated ENA-78/CXCL5, recruits monocytes. PMID: 24943990
31. CXCL5 showed a statistically significant prognostic effect PMID: 24500664
32. mRNA and protein of CXCL5 is increased in bladder tumor tissues and cell lines; down-regulation of CXCL5 resulted in significantly decreased cell proliferation, migration and increased cell apoptosis through Snail, PI3K-AKT and ERK1/2 signaling pathways. PMID: 24583128
33. Knockdown of HSP27 by shRNA decreased HB-EGF plus CXCL5-mediated tumor spheroid formation in a three-dimensional culture system, suggesting that AKT/HSP27 was required for HB-EGF/CXCL5-mediated cancer progression PMID: 24346967
34. Liver cancer cells with high metastatic potential have a higher expression of CXCL5. Exogenous CXCL5 can increase the proliferation, migration and invasion of liver cancer cells with low metastatic potential. PMID: 23290114
35. sCXCL5 level was determined to be an independent prognostic factor for NPC patients PMID: 23469080
36. Increased levels of CXCL5 contribute to enhanced levels of RANKL expression in Paget's disease of bone. PMID: 23439434
37. CXCL5 gene polymorphisms are functional and associated with variable blood pressure in cardiovascular disease-free individuals. PMID: 23245743
38. CXCL5 promotes HCC cell proliferation, invasion, and intratumoral neutrophil infiltration. PMID: 22711685
39. Preoperative serum CXCL5 could serve as a novel predictive marker for prognosis determination of colorectal cancer patients. PMID: 22197219
40. Endothelial production of both ENA-78 and IL-8 was induced by the proinflammatory cytokine IL-1beta. PMID: 22274300
41. Serum CXC ligand 5 is a new marker of subclinical atherosclerosis in type 2 diabetes. PMID: 21609350
42. Blockade of CXCL5 can modulate IL-17-induced arthritic inflammation in part by reducing joint blood vessel formation through a non-overlapping IL-17 mechanism. PMID: 21779896
43. Data demonstrate that the chemokine CXCL5 is a peripheral mediator of UVB-induced inflammatory pain, likely in humans as well as rats. PMID: 21734176
44. Plasma CXCL5 levels are lower in patients with chronic liver disease, suggesting that CXCL5 might be involved in the pathogenesis of chronic liver disease. PMID: 21332547
45. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. PMID: 20945384
46. Report influence of troglitazone, sodium butyrate, 5-aminosalicylic acid and BAY 11-7082 on the chemokine ENA-78/CXCL5 secretion in the intestinal subepithelial myofibroblasts. PMID: 21229889
47. CD14 and CXCL5 were both expressed in tunica intima and tunica adventitia of adipose tissue blood vessels; CXCL5 exhibited chemoattractant and angiogenic properties. PMID: 21034724
48. The highly divergent effects of modifications of CXCL5 on neutrophil influx underline the potential importance of tissue-specific interactions between chemokines and PAD or proteases. PMID: 20630876
49. expression in gingival epithelial cells is induced by thrombin via activation of protease-activated receptor 1 PMID: 19567485
50. Elevated circulating CXCL5 concentrations were associated with higher risk of hypercholesterolemia in middle-aged and elderly Chinese independent of obesity, inflammation, adipokines, and other risk factors but not insulin resistance. PMID: 20501684
顯示更多

收起更多
亞細(xì)胞定位：

Secreted.
蛋白家族：

Intercrine alpha (chemokine CxC) family
數(shù)據(jù)庫鏈接：

HGNC: 10642

OMIM: 600324

KEGG: hsa:6374

STRING: 9606.ENSP00000296027

UniGene: Hs.89714

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human